FDA Allows Emergency Use of Remdesivir to Treat CCP Virus Patients

A vial of the drug remdesivir is visually inspected at a Gilead manufacturing site in March 2020. Gilead Sciences via AP

The Food and Drug Administration (FDA) granted an emergency authorization for Gilead Sciences’s remdesivir to treat the CCP virus.

FDA officials “determined it reasonable that remdesivir may be effective in treating COVID-19,” FDA Commissioner Dr. Stephen Hahn said in a statement.